Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates inter-alpha inhibitor proteins combined with antimicrobials protect against anthrax lethality in mice, highlighting potential as an adjuvant therapy.
Human inter-α inhibitor proteins are endogenous human plasma proteins that function as serine protease inhibitors. Inter-α inhibitor proteins can block the systemic release of proteases in sepsis and block furin-mediated assembly of protective antigen, an essential stop in the intracellular delivery of the anthrax exotoxins, lethal toxin and edema toxin. Inter-α inhibitor proteins administered on hour or up to 24 h after spore challenge with Bacillus anthracis Sterne strain protected mice from lethality if administered with antimicrobial therapy (P < 0.001). These human plasma proteins possess combined actions against anthrax as general inhibitors of excess serine proteases in sepsis and specific inhibitors of anthrax toxin assembly. Inter-α inhibitor proteins could represent a novel adjuvant therapy for the treatment of established anthrax infection.
No takes yet. Share an insight, caveat, or question.
Opal et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: